Joint pain reduction at ultra-low 20 mg dose
An 8-week clinical study confirmed Q-Actin® at just 20 mg/day significantly reduced mild-to-moderate joint pain in adults, supporting mobility and joint comfort. This dose efficiency — 20 mg vs. 1,500 mg for glucosamine or 2,000–4,000 mg for collagen — makes Q-Actin® exceptionally valuable for capsule and tablet formulations where joint health ingredient doses typically dominate the formula.
Anti-inflammatory joint support
Cucumber cucurbitacins (tetracyclic triterpenoids) inhibit COX-2 enzyme and suppress pro-inflammatory prostaglandin production — providing anti-inflammatory joint protection through the same pathway as NSAIDs but from a food-derived natural botanical source. The combination of cucurbitacins and hydroxycinnamic acids (caffeic acid, coumaric acid) in Q-Actin® provides complementary anti-inflammatory mechanisms.
Mobility and functional improvement
The clinical study confirmed that beyond pain reduction, Q-Actin® supplementation improved functional mobility metrics — range of motion, ease of movement, and ability to perform daily activities — reflecting genuine joint function improvement rather than only symptom masking.
Cucurbitacin COX-2 inhibition and hydroxycinnamic acid anti-inflammatory activity
Q-Actin®'s standardized cucurbitacins inhibit NF-κB nuclear translocation and downstream COX-2 enzyme expression — reducing prostaglandin E2 (PGE2) production that sensitizes pain receptors and drives synovial inflammation. Caffeic acid and other hydroxycinnamic acids in the cucumber extract provide complementary 5-LOX inhibition and free radical scavenging, addressing multiple inflammatory pathways relevant to joint pain and degradation simultaneously.
Clinical study examining Q-Actin® (20 mg/day) effects on mild-to-moderate joint pain and mobility in adults over 8 weeks.
Adults with mild-to-moderate joint pain. 8-week clinical study.
Q-Actin® at 20 mg/day significantly reduced joint pain scores and improved mobility vs. baseline at 8 weeks. Ultra-low dose efficacy confirmed for joint comfort application. Well-tolerated with no significant adverse effects.